Surveillance for antimicrobial resistance: VIRA study;Vigilancia de resistencias a los antimicrobianos: Estudio VIRA

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 20, Issue 10, 2002, Pages 503-510

  Picazo, Juan J ^a   Betriu, Carmen ^a   Rodríguez Avial, Iciar ^a   Azahares, Enrique ^a   Ali Sánchez, Blas ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Antimicrobials; Resistance; Surveillance

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFEPIME; CEFOTAXIME; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; IMIPENEM; JOSAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; NORFLOXACIN; PENICILLIN G; RIFAMPICIN; TELITHROMYCIN; TETRACYCLINE; TICARCILLIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; HEALTH SURVEY; INCIDENCE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; SPAIN; STRAIN DIFFERENCE;

EID: 0036905958     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0213-005x(02)72853-x     Document Type: Article

References (28)

1. Baquero F, García-Rodríguez JA, García de Lomas J, Aguilar L. Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: Results of a 1-year (1996-1997) multicenter surveillance study. The Spanish Surveillance Group for Respiratory Pathogens. Antimicrob Agents Chemother 1999;43:357-9.
2. Bouza E, García-Garrote F, Cercenado E, Marín M, Díaz MS. Pseudomonas aeruginosa: A survey of resistance in 136 hospitals in Spain. The Spanish Pseudomonas aeruginosa Study Group. Antimicrob Agents Chemother 1999;43:981-2.
3. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, et al. Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32:S114-32.
4. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: A three-year analysis. Clin Infect Dis 1999;29:239-44.
5. Schmitz F, Verhoef J, Fluit A. Geographical distribution of quinolone resistance among Staphylococcus aureus, Escherichia coli and Klebsiella spp. isolates from 20 European university hospitals. SENTRY Participants Group. J Antimicrob Chemother 1999;43:431-4.
6. th Ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards. Wayne, 2000.
7. National Committee for Clinical Laboratory Standards. Performance Standard for Antimicrobial Susceptibility Testing. Twelfth Informational Supplement. M100-S12. National Committee for Clinical Laboratory Standards. Wayne, 2002.
8. Seppälä H, Nissinen A, Yu Q, Huovinen P. Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland. J Antimicrob Chemother 1993;32:885-91.
9. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: Hospital prevalence and susceptibility patterns. Rev Infect Dis 1988;10:867-78.
10. Oteo J, Alos JI, Gomez-Garces JL. Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: A multicentre surveillance study. J Antimicrob Chemother 2001;47:215-8.
11. Ho PL, Yung RW, Tsang DN, Que TL, Ho M, Seto WH, et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: Results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother 2001;48:659-65.
12. Liñares J, De la Campa AG, Pallarés R. Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med 1999;341:1546-7.
13. Pankuch GA, Visalli MA, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob Agents Chemother 1998;42:624-30.
14. Morosini MI, Canton R, Loza E, Negri MC, Galan JC, Almaraz F, et al. In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanisms. Antimicrob Agents Chemother 2001;45:2427-31.
15. Betriu C, Redondo M, Boloix A, Gomez M, Culebras E, Picazo JJ. Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci. J Antimicrob Chemother 2001;48:911-3.
16. Gemmell CG. Susceptibility of a variety of clinical isolates to linezolid: A European inter-country comparison. J Antimicrob Chemother 2001;48:47-52.
17. Cercenado E, García-Garrote F, Bouza E. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates. J Antimicrob Chemother 2001;47:77-81.
18. Low DE, Keller N, Barth A, Jones RN. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: Results from the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32(Suppl 2):S133-45.
19. Marco F, García de Lomas J, Garcia-Rey C, Bouza E, Aguilar L, Fernandez-Mazarrasa C. Antimicrobial susceptibilities of 1,730 Haemophilus influenzae respiratory tract isolates in Spain in 1998-1999. Antimicrob Agents Chemother 2001;45:3226-8.
20. Alos JI, Oteo J, Aracil B, Gomez-Garces JL. Comparative in vitro study of the activity of moxifloxacin and other antibiotics against 150 strains of penicillin non-susceptible Streptococcus pneumoniae and against 110 strains of ampicillin-resistant Haemophilus influenzae isolated in 1999-2000 in Spain. J Antimicrob Chemother 2001;48:145-8.
21. Perea EJ, García MC, Clavijo MJ, Piédrola G, Campos J, García-Rodríguez JA, et al. Resistencias en haemophilus influenzae en españa. Segundo estudio (1990). Enferm Infecc Microbiol Clin 1993;11:19-28.
22. Doern GV, Brueggemann AB, Pierce G, Holley HP, Rauch A. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: Results of a national multicenter surveillance study. Antimicrob Agents Chemother 1997;41:292-7.
23. Turnak MR, Bandak SI, Bouchillon SK, Allen BS, Hoban DJ. Antimicrobial susceptibilities of clinical isolates of Haemophilus influenzae and Moraxella catarrhalis collected during 199-2000 from 13 countries. Clin Microbiol Infect 2001;7:671-7.
24. Betriu C, Rodriguez-Avial I, Sanchez BA, Gomez M, Alvarez J, Picazo JJ, et al. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob Agents Chemother 2002;46:892-5.
25. Fluit AC, Verhoef J, Schmitz FJ. Antimicrobial resistance in European isolates of Pseudomonas aeruginosa. European SENTRY Participants. Eur J Clin Microbiol Infect Dis 2000;19:370-4.
26. Ramphal R, Hoban DJ, Pfaller MA, Jones RN. Comparison of the activity of two broad-spectrum cephalosporins tested against 2,299 strains of Pseudomonas aeruginosa isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998. Diagn Microbiol Infect Dis 2000;36:125-9.
27. Valero E, Sevillano D, Calvo A, García R, Leturia A, Gómez Lus ML. Actividad de las nuevas fluoroquinolonas frente a aislamiento clínicos de Acinetobacter baumannii. Rev Esp Quimioterap 2001;14:358-63.
28. López-Hernández S, Alarcón T, López-Brea M. Evolución de la sensibilidad antimicrobiana en aislamientos clínicos de Acinetobacter baumannii (1995-1997). Rev Esp Quimioterap 2000;13:394-400.